Literature DB >> 8207201

Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2.

N Oppenheimer-Marks1, A F Kavanaugh, P E Lipsky.   

Abstract

To determine whether part of the anti-inflammatory effects of prostaglandin E2 (PGE2) was related to inhibition of T cell interactions with endothelial cells (EC), the effects of PGE2 and other cAMP-elevating agents on the transendothelial migration of human T cells was examined. Although PGE2 did not effect T cell binding to EC, concentration-dependent inhibition of the transendothelial migration of T cells through unstimulated or IL-1-activated EC was observed. PGE2 inhibited the function of both T cells and EC, with maximal inhibition observed when both T cells and EC were treated with PGE2. However, the inhibitory action of PGE2 could not be ascribed to an effect on the adhesion receptor pair, CD11a/CD18-CD54. The inhibitory effect of PGE2 seemed to relate to its capacity to elevate cellular cAMP levels, because 3-isobutyl-1-methylxanthine enhanced PGE2 activity and dibutyryl cAMP and forskolin also inhibited transendothelial migration. The inhibitory effect of PGE2 and the other cAMP-elevating agents on the function of T cells related in part to suppression of their intrinsic locomotory behavior as random migration in the absence of EC was blocked. In EC, PGE2 and the other cAMP-elevating agents increased the barrier function of EC as evidenced by a decrease in the diffusion of [3H]mannitol through the endothelium. These results indicate that part of the anti-inflammatory action of PGE2 relates to its capacity to suppress the transendothelial migration of T cells by cAMP-mediated alterations in the function of both T cells and EC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207201

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Prostaglandin E2 and monoclonal antibody to lymphocyte function-associated antigen-1 differentially inhibit migration of T lymphocytes across microvascular retinal endothelial cells in rat.

Authors:  M Mesri; J Liversidge; J V Forrester
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

Review 2.  Regulation of immune responses by prostaglandin E2.

Authors:  Pawel Kalinski
Journal:  J Immunol       Date:  2012-01-01       Impact factor: 5.422

3.  Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors.

Authors:  Ying-Ji Li; Xing-Qi Wang; Tadashi Sato; Nobuhiro Kanaji; Masanori Nakanishi; Miok Kim; Joel Michalski; Amy J Nelson; Jian-Hong Sun; Maha Farid; Hesham Basma; Amol Patil; Myron L Toews; Xiangde Liu; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2010-03-04       Impact factor: 6.914

4.  Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.

Authors:  Ryan T Dackor; Jennifer Cheng; James W Voltz; Jeffrey W Card; Catherine D Ferguson; Ryan C Garrett; J Alyce Bradbury; Laura M DeGraff; Fred B Lih; Kenneth B Tomer; Gordon P Flake; Gregory S Travlos; Randle W Ramsey; Matthew L Edin; Daniel L Morgan; Darryl C Zeldin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-19       Impact factor: 5.464

5.  Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia.

Authors:  C Bandeira-Melo; Y Singh; R S Cordeiro; P M e Silva; M A Martins
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.

Authors:  J Wilborn; L J Crofford; M D Burdick; S L Kunkel; R M Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 7.  Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3.

Authors:  Laurence S Harbige
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

Review 8.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

9.  Inhibition of Rac activation as a mechanism for negative regulation of actin cytoskeletal reorganization and cell motility by cAMP.

Authors:  Shin-ya Nagasawa; Noriko Takuwa; Naotoshi Sugimoto; Hiroshi Mabuchi; Yoh Takuwa
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

Review 10.  Airway smooth muscle in asthma: just a target for bronchodilation?

Authors:  Judith L Black; Reynold A Panettieri; Audreesh Banerjee; Patrick Berger
Journal:  Clin Chest Med       Date:  2012-07-11       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.